Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis - Trial NCT06405685
Access comprehensive clinical trial information for NCT06405685 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 2
Apr 27, 2023
Oct 30, 2025
Primary Outcome
R0 resection rate
Summary
This is a prospective, open-label, single arm clinical study. The main purpose of the study
 is to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG in the
 treatment of pancreatic cancer with liver metastasis. Patients will receive Nimotuzumab plus
 AG as conversion therapy, and imaging assessments (according to RECIST V.1.1 criteria) will
 be performed every two cycles (every two months) of conversion therapy. The main endpoint is
 R0 resection rate. Additional end points included resection rates, overall survival (OS),
 objective response rate (ORR), safety, etc.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06405685
Non-Device Trial